Brexit: EU Commission warns on possible issues regarding clinical trials
Many uncertainties are expected in the filed of clinical trials, while the date of the Brexit is approaching. The European Commission released a Notice to stakeholders to provide guidance to companies. A Q&A document is also available discussing the sourcing from the UK of innovator pharmaceutical products to be used in bioequivalence studies of generics outside UK. Finally, UK's MHRA has launched a public consultation on how to adapt the country's regulatory framework in the case of a "no deal" exit.